SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q1 2024 vs. Q4 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 10 | 12 | +2 |
| Shares | 1.26M | 1.17M | −95.2K (−7.6%) |
| Value | $38.1K | $43.8K | +$5.75K (+15.1%) |
New holders (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 12,366 | $482 | 0.00% |
| Clear Street LLC | 100 | $4 | 0.00% |
| Bank of America Corp | 100 | $3 | 0.00% |
Sold out (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| UBS Group AG | 29,080 | $872 |